Long-Acting Basal Insulins for Patients with Diabetes: Distinguishing Formulations for Individualized Care
Vivian Fonseca, MD
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
This online activity is focused on the team involved in healthcare practitioners who manage and treat patients with diabetes.
The target audience for this program is primary care providers (internal medicine, family practice MD/DOs), endocrinologists, and other health care practitioners including nurse practitioners, physician assistants, pharmacists, and certified diabetes educators.
After completing the CME activity, learners should be better able to:
- Assess current diabetes guidelines to best implement evidence-based strategies in diabetes
- Review and distinguish current long-acting formulations of insulin therapy and incorporate these agents into a comprehensive treatment plan for patients with T2DM
- Identify barriers to treatment intensification and patient/provider communication for patients with T2DM
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Credit Designation Statement
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses who manage and treat patients with diabetes.
Credits: 1.0 ANCC Contact Hours.
CNE Accreditation Statement
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Vivian Fonseca, MD, receives research support (to Tulane) and grants from Bayer and Boehringer Ingelheim. Dr. Fonseca receives honorarium for consulting and lectures from Takeda, Novo Nordisk, Sanofi-Aventis, Eli Lilly, Abbott, AstraZeneca, Intarcia, and Ashai. His stock options are Microbiome Technologies, Insulin Algorithms, BRAVO4Health and has stocks with Amgen.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse.
The reviewer has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Cindy Lampner, Director of Medical and Scientific Services, has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the pre-and-post surveys and evaluation.
Participants will receive their certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at https://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: August 16, 2019
EXPIRATION DATE: August 16, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.